http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 02 Jul 2026 16:34:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Adler+Reid+G./26728579.html si-local-file:///var/storage/secattach/20260702/26728579.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Adler+Reid+G./26728579.html Thu, 02 Jul 2026 16:34:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Adler+Reid+G./26728579.html si-local-file:///var/storage/secattach/20260702/26728579.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Adler+Reid+G./26728579.html Thu, 02 Jul 2026 16:34:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Singh+Shawn/26728040.html si-local-file:///var/storage/secattach/20260702/26728040.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Singh+Shawn/26728040.html Thu, 02 Jul 2026 16:17:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Singh+Shawn/26728040.html si-local-file:///var/storage/secattach/20260702/26728040.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Singh+Shawn/26728040.html Thu, 02 Jul 2026 16:17:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Tressler+Nick+B./26728063.html si-local-file:///var/storage/secattach/20260702/26728063.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Tressler+Nick+B./26728063.html Thu, 02 Jul 2026 16:17:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Tressler+Nick+B./26728063.html si-local-file:///var/storage/secattach/20260702/26728063.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Tressler+Nick+B./26728063.html Thu, 02 Jul 2026 16:17:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30/26710126.html si-local-file:///var/storage/secattach/20260630/26710126.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30/26710126.html Tue, 30 Jun 2026 08:29:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30/26710126.html si-local-file:///var/storage/secattach/20260630/26710126.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+30/26710126.html Tue, 30 Jun 2026 08:29:00 -0400 O.07328903 VTGN http://www.streetinsider.com/FDA/Vistagen%27s+fasedienol+misses+Phase+3+endpoints+in+anxiety+trial/26709912.html <p>Vistagen (Nasdaq: VTGN) announced that its intranasal drug candidate fasedienol failed to meet the primary and secondary endpoints in the PALISADE-4 Phase 3 clinical trial for the acute treatment of social anxiety disorder.</p> <p>The multi-center, randomized, double-blind, placebo-controlled trial enrolled 238 adult patients and used the Subjective Units of Distress Scale (SUDS) as the primary endpoint during a simulated public speaking challenge. The least squares mean change from baseline was -9.5 for fasedienol versus -11.4 for placebo, a difference of 1.9 points that was not statistically significant (p=0.427).</p> <p>In a post-hoc analysis of a subgroup of 123 patients with very severe social http://www.streetinsider.com/FDA/Vistagen%27s+fasedienol+misses+Phase+3+endpoints+in+anxiety+trial/26709912.html Tue, 30 Jun 2026 08:01:26 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/FDA/Vistagen%27s+fasedienol+misses+Phase+3+endpoints+in+anxiety+trial/26709912.html <p>Vistagen (Nasdaq: VTGN) announced that its intranasal drug candidate fasedienol failed to meet the primary and secondary endpoints in the PALISADE-4 Phase 3 clinical trial for the acute treatment of social anxiety disorder.</p> <p>The multi-center, randomized, double-blind, placebo-controlled trial enrolled 238 adult patients and used the Subjective Units of Distress Scale (SUDS) as the primary endpoint during a simulated public speaking challenge. The least squares mean change from baseline was -9.5 for fasedienol versus -11.4 for placebo, a difference of 1.9 points that was not statistically significant (p=0.427).</p> <p>In a post-hoc analysis of a subgroup of 123 patients with very severe social http://www.streetinsider.com/FDA/Vistagen%27s+fasedienol+misses+Phase+3+endpoints+in+anxiety+trial/26709912.html Tue, 30 Jun 2026 08:01:26 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/FDA/Vistagen%27s+fasedienol+misses+Phase+3+endpoints+in+anxiety+trial/26709912.html <p>Vistagen (Nasdaq: VTGN) announced that its intranasal drug candidate fasedienol failed to meet the primary and secondary endpoints in the PALISADE-4 Phase 3 clinical trial for the acute treatment of social anxiety disorder.</p> <p>The multi-center, randomized, double-blind, placebo-controlled trial enrolled 238 adult patients and used the Subjective Units of Distress Scale (SUDS) as the primary endpoint during a simulated public speaking challenge. The least squares mean change from baseline was -9.5 for fasedienol versus -11.4 for placebo, a difference of 1.9 points that was not statistically significant (p=0.427).</p> <p>In a post-hoc analysis of a subgroup of 123 patients with very severe social http://www.streetinsider.com/FDA/Vistagen%27s+fasedienol+misses+Phase+3+endpoints+in+anxiety+trial/26709912.html Tue, 30 Jun 2026 08:01:26 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/FDA/Vistagen%27s+fasedienol+misses+Phase+3+endpoints+in+anxiety+trial/26709912.html <p>Vistagen (Nasdaq: VTGN) announced that its intranasal drug candidate fasedienol failed to meet the primary and secondary endpoints in the PALISADE-4 Phase 3 clinical trial for the acute treatment of social anxiety disorder.</p> <p>The multi-center, randomized, double-blind, placebo-controlled trial enrolled 238 adult patients and used the Subjective Units of Distress Scale (SUDS) as the primary endpoint during a simulated public speaking challenge. The least squares mean change from baseline was -9.5 for fasedienol versus -11.4 for placebo, a difference of 1.9 points that was not statistically significant (p=0.427).</p> <p>In a post-hoc analysis of a subgroup of 123 patients with very severe social http://www.streetinsider.com/FDA/Vistagen%27s+fasedienol+misses+Phase+3+endpoints+in+anxiety+trial/26709912.html Tue, 30 Jun 2026 08:01:26 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html <p class="bwalignc"> <i>Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints</i> </p><p class="bwalignc"> <i>In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder</i> </p><p class="bwalignc"> <i>Favorable safety and tolerability data were consistent with previous clinical trials</i> </p><p class="bwalignc"> <i>Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering http://www.streetinsider.com/Press+Releases/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html Tue, 30 Jun 2026 08:00:00 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html <p class="bwalignc"> <i>Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints</i> </p><p class="bwalignc"> <i>In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder</i> </p><p class="bwalignc"> <i>Favorable safety and tolerability data were consistent with previous clinical trials</i> </p><p class="bwalignc"> <i>Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering http://www.streetinsider.com/Press+Releases/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html Tue, 30 Jun 2026 08:00:00 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html <p class="bwalignc"> <i>Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints</i> </p><p class="bwalignc"> <i>In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder</i> </p><p class="bwalignc"> <i>Favorable safety and tolerability data were consistent with previous clinical trials</i> </p><p class="bwalignc"> <i>Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering http://www.streetinsider.com/Press+Releases/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html Tue, 30 Jun 2026 08:00:00 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html <p class="bwalignc"> <i>Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints</i> </p><p class="bwalignc"> <i>In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder</i> </p><p class="bwalignc"> <i>Favorable safety and tolerability data were consistent with previous clinical trials</i> </p><p class="bwalignc"> <i>Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering http://www.streetinsider.com/Press+Releases/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html Tue, 30 Jun 2026 08:00:00 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/Business+Wire/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html <p class="bwalignc"> <i>Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints</i> </p><p class="bwalignc"> <i>In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder</i> </p><p class="bwalignc"> <i>Favorable safety and tolerability data were consistent with previous clinical trials</i> </p><p class="bwalignc"> <i>Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering http://www.streetinsider.com/Business+Wire/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html Tue, 30 Jun 2026 08:00:00 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/Business+Wire/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html <p class="bwalignc"> <i>Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints</i> </p><p class="bwalignc"> <i>In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder</i> </p><p class="bwalignc"> <i>Favorable safety and tolerability data were consistent with previous clinical trials</i> </p><p class="bwalignc"> <i>Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering http://www.streetinsider.com/Business+Wire/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html Tue, 30 Jun 2026 08:00:00 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/Business+Wire/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html <p class="bwalignc"> <i>Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints</i> </p><p class="bwalignc"> <i>In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder</i> </p><p class="bwalignc"> <i>Favorable safety and tolerability data were consistent with previous clinical trials</i> </p><p class="bwalignc"> <i>Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering http://www.streetinsider.com/Business+Wire/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html Tue, 30 Jun 2026 08:00:00 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/Business+Wire/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html <p class="bwalignc"> <i>Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints</i> </p><p class="bwalignc"> <i>In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder</i> </p><p class="bwalignc"> <i>Favorable safety and tolerability data were consistent with previous clinical trials</i> </p><p class="bwalignc"> <i>Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering http://www.streetinsider.com/Business+Wire/Vistagen+Announces+Topline+and+Post-Hoc+Data+from+PALISADE-4+Phase+3+Public+Speaking+Challenge+Trial+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/26709853.html Tue, 30 Jun 2026 08:00:00 -0400 A.06822034 O.07328903 O.20026344 VTGN http://www.streetinsider.com/Trading+Halts/VistaGen+Therapeutics+%28VTGN%29++Halted%2C+News+Pending/26709725.html <p>VistaGen Therapeutics (NASDAQ: VTGN) Halted, News Pending<br /> </p> http://www.streetinsider.com/Trading+Halts/VistaGen+Therapeutics+%28VTGN%29++Halted%2C+News+Pending/26709725.html Tue, 30 Jun 2026 07:58:30 -0400 VTGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+16/26660927.html si-local-file:///var/storage/secattach/20260617/26660927.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+16/26660927.html Wed, 17 Jun 2026 17:14:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+16/26660927.html si-local-file:///var/storage/secattach/20260617/26660927.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Jun+16/26660927.html Wed, 17 Jun 2026 17:14:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Vistagen+Therapeutics%2C++++For%3A+Mar+31/26648190.html si-local-file:///var/storage/secattach/20260615/26648190.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Vistagen+Therapeutics%2C++++For%3A+Mar+31/26648190.html Mon, 15 Jun 2026 16:50:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Vistagen+Therapeutics%2C++++For%3A+Mar+31/26648190.html si-local-file:///var/storage/secattach/20260615/26648190.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Vistagen+Therapeutics%2C++++For%3A+Mar+31/26648190.html Mon, 15 Jun 2026 16:50:00 -0400 O.07328903 VTGN